找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

123456
返回列表
打印 上一主題 下一主題

Titlebook: Critical Issues in Head and Neck Oncology; Key Concepts from th Jan B. Vermorken,Volker Budach,Brian O‘Sullivan Conference proceedings‘‘‘‘‘

[復(fù)制鏈接]
樓主: 叛亂分子
51#
發(fā)表于 2025-3-30 09:50:09 | 只看該作者
Gregor Domes,Beate Ditzen,Jürgen Bartheal, nasopharyngeal, sinonasal, periorbital, and salivary gland cancer. The limited broad availability of this treatment method and its unknown cost-effectiveness need to be evaluated. In this chapter, we discuss the currently available evidence of PT for HNCs and viable options to generate further
52#
發(fā)表于 2025-3-30 13:04:39 | 只看該作者
Entscheidungen vor dem Schreiben,rboplatin with or without 5-fluorouracil, taxanes or cetuximab). However, none of these have shown superior results over the use of cisplatin in randomized trials. Late toxicity is a major downside of CCRT, and this is most worrying for those with the highest chance of cure, i.e. low-risk human papi
53#
發(fā)表于 2025-3-30 18:08:56 | 只看該作者
54#
發(fā)表于 2025-3-30 22:03:25 | 只看該作者
, overall survival following SBRT-based reirradiation remains moderate, which might be due to insufficient doses. There is thus a need for well-designed trials of SBRT-based reirradiation in terms of dose escalation and combination with systemic therapy. In HNC, the evidence for treatment of oligome
55#
發(fā)表于 2025-3-31 02:15:56 | 只看該作者
,Elektra: Des ?dipus geistige Schwester,ent in most cases, along with radiotherapy and chemotherapy. Biotherapy and immunotherapy are only anecdotally and compassionately used. For each histology, a careful selection of modalities and their timing is paramount to ensure the best chance of cure. In keeping with the principles of precision
56#
發(fā)表于 2025-3-31 05:43:44 | 只看該作者
Zaher Jandali,Klaus Müller,Lucian Jigaonent in the multidisciplinary management of MiSGMTs, and its possible use should be considered. For selected naso-ethmoidal MiSGMTs, especially adenoid cystic carcinoma of the ethmoid, small case series have supported the use of endoscopic transnasal surgery. Similarly, it has been shown that MiSGM
57#
發(fā)表于 2025-3-31 12:31:37 | 只看該作者
58#
發(fā)表于 2025-3-31 13:22:59 | 只看該作者
Immune Checkpoint Inhibition and Radiotherapy in Head and Neck Squamous Cell Carcinoma: Synergisms l researchers currently aims at the development and evaluation of combined modality treatment approaches. Radiotherapy is a highly promising partner in this regard and represents a crucial treatment modality for patients with locally advanced HNSCC. Historically established as cytotoxic anti-cancer
59#
發(fā)表于 2025-3-31 18:13:16 | 只看該作者
60#
發(fā)表于 2025-4-1 00:14:45 | 只看該作者
How to Standardize Molecular Profiling Programs for Routine Patient Care,nical judgement. All steps described above are not standardized, resulting in relevant heterogeneity in treatment recommendations among MTBs in different institutions..In this chapter, contemporary challenges will be discussed, including intratumoral heterogeneity, use of diverse molecular diagnosti
123456
返回列表
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-16 00:09
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
云林县| 烟台市| 扶绥县| 疏附县| 紫阳县| 廊坊市| 大悟县| 博兴县| 柘城县| 乌拉特前旗| 双城市| 瑞安市| 区。| 南澳县| 迁安市| 巴东县| 万源市| 常德市| 名山县| 红安县| 冕宁县| 大新县| 大邑县| 新兴县| 吴川市| 会昌县| 鹤壁市| 那坡县| 济宁市| 正安县| 科技| 鄂托克前旗| 隆昌县| 芮城县| 靖宇县| 应用必备| 蓝山县| 闸北区| 乌兰县| 泰安市| 崇州市|